Lonidamine

CAT: 804-HY-B0486-01Size: 5 mgDry Ice: NoHazardous: No
5 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM) . Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis[1][2][3].
CAS Number
[50264-69-2]
Product Name Alternative
AF-1890; Diclondazolic Acid; DICA
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Hexokinase; Mitochondrial Metabolism; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lonidamine.html
Purity
99.91
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O
Molecular Formula
C15H10Cl2N2O2
Molecular Weight
321.16
Precautions
H302, H315, H319, H335
References & Citations
[1]Nancolas B, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016 Apr 1;473 (7) :929-36. |[2]Ilya A Shutkov, et al. Ru (III) Complexes with Lonidamine-Modified Ligands. Int J Mol Sci. 2021 Dec 15;22 (24) :13468. |[3]Xueqian Yin, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β. Sci Signal. 2019 Dec 17;12 (612) :eaax4067. |[4]Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10 (1) :2205.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Related Products

CatalogName